



BioNews 100,000 stories

BioWeb 4 million pages

Companies

Channels
Select Channel -----> <input type="text"/>
News Stories
Select News -----> <input type="text"/>
News by Region -----> <input type="text"/>
News by Source -----> <input type="text"/>
News by Topic -----> <input type="text"/>
Health News -----> <input type="text"/>
Career Center
Select Career -----> <input type="text"/>
Event Center
Select Event -----> <input type="text"/>
Executive Reports
Select Reports -----> <input type="text"/>
Directories
Select Directories --> <input type="text"/>
Drug Discovery
R&D Information -----> <input type="text"/>
Investors
Select Services -----> <input type="text"/>
Disease Search
Select Disease -----> <input type="text"/>
Membership
Membership Options> <input type="text"/>
Search
Search Resources --> <input type="text"/>
General
Select General -----> <input type="text"/>

Medical Device Innovations closes £2.9m funding round

Chester, UK, 2nd March, 2005 - Medical Device Innovations Ltd (MDi), the intellectual property development company focused on medical devices, has announced the completion of its Series A financing round, raising £2.9 million. This round was led by existing seed investor, Avlar Bioventures, alongside new monies from a fund managed by YFM Private Equity Limited. MDi received £0.5m seed finance led by Avlar in 2002.

MDi acquires the intellectual property relating to a new medical device and develops the device to proof of concept stage. Adding value in the transition between the inventor and the medical device companies, MDi progresses inventions which might not normally be broad based enough to form the basis of a company or are at too early a stage to out licence to established medical device companies.

Once a device has been advanced to proof of principle stage it will be either licenced or sold to a major device company or grouped with synergistic projects as the basis for a spin out company.

MDi manages multiple projects simultaneously and currently has six in its portfolio. Applications under development include radiology, cancer treatment, orthopaedic/plastic surgery and emergency medicine.

MDi CEO, David Cottier commented, "As the first company in Europe set up purely to source

and develop innovative new medical technologies, we are encouraged and excited to have successfully completed this round of financing. It provides further endorsement of the MDi business and recognition of the significant opportunities in interventional medical devices.

Ads by Goooooogle

Biotechnology news
BioWorld Today is here!
News, data and company information.
www.BioWorld.com

Pharmaceutical Sales
Do You Want a Pharma Sales Job? You Must Prepare for the Interview.
www.pharmalanding.com

Biotech Jobs
Search over 4500 job opportunities at over 500 companies worldwide.
www.hirehealth.com

UK Biotech Sales Jobs
Over 400 direct vacancies
Zenith on 0870 787 8877
www.zenopa.com

Riva GB Ltd
Manufacturers of tablet presses for R&D small scale and production.
www.rivapress.co.uk

- Ad Links by Google**
- [Biotechnology Course](#)
 - [Biotechnology in India](#)
 - [Pharmaceutical News](#)
 - [Pharmaceutical Careers](#)
 - [Biotechnology Meetings](#)

These funds will enable us to source more new projects and accelerate the development of current ones.”

Dan Roach of Avlar Bioventures commented, “MDi will rapidly develop and introduce new products that improve existing technologies and address new therapeutic areas. The financial resources now available to the team will accelerate this process.”

Doug Stelman of YFM Private Equity comments, “Medical technology varies from the very sophisticated to the quite simple but clever idea. The major medical equipment suppliers are investing heavily in improving patient care but it is often the medical professionals closest to delivery that have the best ideas. This is why we see the strong commercial potential in the MDi approach to bringing these ideas forward and they have the medical device industry expertise to spot the likely winners. The North West Business Investment Scheme, managed by YFM Private Equity Limited, is pleased to join existing investors in this second round of financing.”

- ends -

Medical Device Innovations Ltd www.mdi-md.com

MDi is an intellectual property management and development company focused on enabling medical device innovations from individual clinicians or academics, to reach the market and become part of routine clinical practice. The essential requirements of financing, project management, prototyping and Intellectual Property management are provided to all selected projects. At the point where a device is advanced enough to interest a major medical device company MDi will sell or out licence the product. At this stage the inventors receive further milestone payments. MDi currently has six projects in its portfolio and is expected to out licence its first project in the second half of 2005. Applications include radiology, cancer treatment and re-constructive surgery.

Avlar BioVentures Ltd www.avlar.com

Avlar is a specialist biotechnology venture capital company, which currently has over £65 million under management in Avlar BioVentures Fund I and Avlar BioVentures Fund II. The two funds are focused on seed and early stage investments and are used to invest in emerging bioscience technologies, notably combinatorial chemistry, functional genomics, gene and cell therapy and drug design. Avlar works intensively with companies in the critical stages of development from pre-formation to second round of financing, applying its strategic, entrepreneurial and

BioBulletin

Reach out to the life science sector - 40,000 life science professionals contacted by email

[Evaluate in more detail!](#)

Life Science Events

100's of life science, biotech and pharma conferences, conventions, workshops, webinars

[Search for events now!](#)

Jain PharmaBiotech

Molecular Diagnostics, Cell Therapy, Proteomics, Neuroprotection, Transdermal Drug Delivery - Technologies, Markets and Companies Report

[Reports updated every month!](#)

After VIOXX

COX-2 withdrawal - Therapeutic, R&D and pharmaceutical impact This report is of interest to researchers, strategic planners, marketing personnel and investors

[Tell me more - now!](#)

biotech industry skills. Currently Avlar Bioventures has ten unquoted investments and four publicly quoted investments.

YFM Private Equity Limited

www.yfmprivateequity.co.uk

YFM Group provides investment capital and business development services to SMEs throughout the UK. We are a leading provider of equity capital for UK based SMEs seeking sums of up to £1 million. We currently have over £250 million in funds and consultancy contracts under management and have over 70 employees, including 36 investment executives. We have offices in Leeds, Manchester, Bristol, London, Sheffield, and Hull. YFM Private Equity Limited and YFM Venture Finance Limited are authorised and regulated by the Financial Services Authority. Information regarding the YFM Group can be found on our website at <http://www.yfmgroup.co.uk> Registered Office: Saint Martins House, 210-212 Chapeltown Road, Leeds LS7 4HZ. Tel: 0113 294 5000, Fax 0113 294 5003, Email info@yfmgroup.co.uk <mailto:info@yfmgroup.co.uk>. Registered in England No. 4848599

North West Business Investment Scheme

www.nwbis.co.uk

The North West Business Investment Scheme and the costs of its management is part financed by the European Union through the European Regional Development Fund Programme 2000-2006 and by the Northwest Development Agency.

Northwest Regional Development Agency

www.nwda.org

The Northwest Regional Development Agency (NWDA) is responsible for the sustainable economic development and regeneration of England's Northwest and has 5 key priorities: Business Development, Regeneration, Skills & Employment, Infrastructure and Image. The Agency has initiated or sponsored a range of complimentary seed and venture capital funds to help new and growing companies.

- ends -

Contacts:

MDi Ltd: David Cottier, CEO Tel: + 44 (0) 1244 893686

Email: dc@mdi-md.com

YFM Private Equity Ltd, Doug Stellman, Investment Manager Tel: +44 (0) 161 832 7603. Email: doug.stellman@yfmgroup.co.uk

Northbank Communications: Sue Charles, Tel:
+ 44 (0) 20 7886 8152

Email:
s.charles@northbankcommunications.com

Fiona Brown, Tel: + 44 (0) 20 7886 8155

Email:
f.brown@northbankcommunications.com

BioNews 100,000
stories
 BioWeb 4 million
pages

Google™

BioPortf
 Web

Select: [Advertising & Sponsorship](#) | [About BioPortfolio](#) | [User Agreement](#)
Post a: [Job](#) | [Resume](#) | [Event](#) | [Press Release](#) | [Company Profile](#) | [URL for BioWeb](#)
Add: [BioWeb and BioNews on your website](#)
Join: BioPortfolio's [Membership Services](#) | [Review our 14 Channels](#)
Receive: [BioBulletin](#) | [News Email Alerts](#) | [DailyUpdates](#)

Have you found BioPortfolio useful? To make a financial contribution [CLICK HERE!](#)

Copyright © 1997-2005 - BioPortfolio Limited.
All rights reserved. All other trademarks recognized.

Email comments and feedback!

[Peter Barfoot](#), Managing Director, BioPortfolio Ltd.

USA Voicemail and Fax:
(+1) 415 680 2472 San Francisco
UK Tel: (+44) 1300 321501 Fax: (+44) 1300 321502



"who, what, where, when and why biotechnology will impact on our lives"
